Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis

Front Cell Dev Biol. 2024 Aug 13:12:1426508. doi: 10.3389/fcell.2024.1426508. eCollection 2024.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown origin and the most common interstitial lung disease. However, therapeutic options for IPF are limited, and novel therapies are urgently needed. Histone deacetylases (HDACs) are enzymes that participate in balancing histone acetylation activity for chromatin remodeling and gene transcription regulation. Increasing evidence suggests that the HDAC family is linked to the development and progression of chronic fibrotic diseases, including IPF. This review aims to summarize available information on HDACs and related inhibitors and their potential applications in treating IPF. In the future, HDACs may serve as novel targets, which can aid in understanding the etiology of PF, and selective inhibition of single HDACs or disruption of HDAC genes may serve as a strategy for treating PF.

Keywords: HDAC inhibitors; fibroblasts; histone acetylation; histone deacetylase; idiopathic pulmonary fibrosis.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors gratefully acknowledge financial support from the National Natural Sciences Foundation of China (Grant numbers: 82200086, 82370077, and 81900070), the Hunan Provincial Natural Science Foundation of China (Grant numbers: 2022JJ40678 and 2023JJ40807). This work was supported by the Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University.